Duvelisib plus venetoclax for relapsed PTCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to treatment. Some types like CTCL or TPLL are not included.
- Your cancer must have gotten worse or returned after at least two prior treatments.
- You must be able to get around and take care of yourself (ECOG performance status 0-2).
- Your kidneys must work well enough (creatinine clearance of 30 mL/min or higher). Your liver must also be working well (AST, ALT, and bilirubin within safe ranges).
- Your blood counts must be high enough—neutrophils (a type of white blood cell) at least 1,000–1,500, platelets at least 50,000, and hemoglobin at least 8 g/dL.
- You cannot have active infections like hepatitis B or C, HIV, or a serious heart condition. You also cannot have been treated with venetoclax or a PI3K inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
This trial tests a combination of three drugs (cladribine, ruxolitinib, and venetoclax) for people with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to prior treatment. The goal is to see if this therapy can help control the disease.
This trial tests whether the drug duvelisib can help keep T-cell lymphoma in remission after initial chemotherapy. It is for people who have finished first-line treatment with a CHOP-like regimen, achieved a complete response, and cannot or choose not to have a stem cell transplant.
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
This trial tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) for people with T-cell lymphoma that has come back or not responded to treatment. Duvelisib is a targeted therapy that may work differently than chemotherapy.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
Hear when a new T-cell Prolymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.